Active Filters

S1826 at ASCO 2023 Plenary Session
Jun 4, 2023
Nivolumab added to AVD chemotherapy expected to become new standard for initial treatment for advanced stage disease in adolescents and adults, based on trial data to be presented at 2023 ASCO Annual Meeting plenary session
Tumor size change and OS correlate linearly
Jun 2, 2023
Changes in RECIST tumor measures correlate linearly with survival in patients treated with checkpoint inhibitors
S1929 results at ASCO
Jun 2, 2023
Results of SWOG S1929 trial show patients with small-cell lung cancer with SLFN11 expression can benefit from PARP inhibitor added to immune checkpoint blockade
S1714 results at ASCO 2023
May 31, 2023
S1714 results at ASCO 2023: Taxane-induced peripheral neuropathy in breast cancer: frequent, clinically significant, and worse with paclitaxel
2023 ASCO Annual Meeting
May 30, 2023
SWOG researchers have also contributed to an additional 11 abstracts on studies led by other groups.
S1011: Less is more in bladder cancer surgery
May 30, 2023
Extended lymph node removal does not benefit patients with clinically localized muscle-invasive bladder cancer
Dr. Primo Lara and Dr. Dawn Hershman
May 16, 2023
Drs. Dawn Hershman and Primo Lara elected group co-chairs-elect of SWOG Cancer Research Network
S1609 DART gynecologic cancer results at AACR 2023
Apr 17, 2023
SWOG researchers report results in rare gynecologic cancers from S1609 DART immunotherapy trial
S1512 Cohort B results at AACR 2023
Apr 16, 2023
SWOG S1512 trial sees high response rate to pembrolizumab in patients with unresectable desmoplastic melanoma